Cheap Broker Fees
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Takeda Pharmaceutical Company Limited is a drug manufacturers-specialty & generic business based in the US. Takeda Pharmaceutical Company shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Takeda Pharmaceutical Company employs 47,099 staff and has a trailing 12-month revenue of around USD$3.3 trillion.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Takeda Pharmaceutical Company's stock price has had significant negative movement.
Its last market close was $14.02, which is 25.39% down on its pre-crash value of $18.79 and 12.79% up on the lowest point reached during the March crash when the stocks fell as low as $12.43.
If you had bought $1,000 worth of Takeda Pharmaceutical Company stocks at the start of February 2020, those stocks would have been worth $689.01 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $724.13.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$14.02|
|52-week range||$14.02 - $19.97|
|50-day moving average||$16.28|
|200-day moving average||$16.77|
|Wall St. target price||$20.37|
|Dividend yield||$180 (4.14%)|
|Earnings per share (TTM)||$1.21|
|1 week (2021-10-15)||-0.57%|
|1 month (2021-09-23)||-18.25%|
|3 months (2021-07-23)||-16.84%|
|6 months (2021-04-23)||-17.82%|
|1 year (2020-10-23)||-15.85%|
|2 years (2019-10-23)||-20.30%|
|3 years (2018-10-23)||20.07|
|5 years (2016-10-21)||22.83|
Valuing Takeda Pharmaceutical Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Takeda Pharmaceutical Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Takeda Pharmaceutical Company shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Takeda Pharmaceutical Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1158. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Takeda Pharmaceutical Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1,031.1 billion.
The EBITDA is a measure of a Takeda Pharmaceutical Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3,345.6 billion|
|Operating margin TTM||16.04%|
|Gross profit TTM||$2,203.6 billion|
|Return on assets TTM||2.65%|
|Return on equity TTM||8.69%|
|Market capitalisation||$44.5 billion|
TTM: trailing 12 months
There are currently 6.5 million Takeda Pharmaceutical Company shares held short by investors – that's known as Takeda Pharmaceutical Company's "short interest". This figure is 12.1% up from 5.8 million last month.
There are a few different ways that this level of interest in shorting Takeda Pharmaceutical Company shares can be evaluated.
Takeda Pharmaceutical Company's "short interest ratio" (SIR) is the quantity of Takeda Pharmaceutical Company shares currently shorted divided by the average quantity of Takeda Pharmaceutical Company shares traded daily (recently around 1.7 million). Takeda Pharmaceutical Company's SIR currently stands at 3.77. In other words for every 100,000 Takeda Pharmaceutical Company shares traded daily on the market, roughly 3770 shares are currently held short.
However Takeda Pharmaceutical Company's short interest can also be evaluated against the total number of Takeda Pharmaceutical Company shares, or, against the total number of tradable Takeda Pharmaceutical Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Takeda Pharmaceutical Company's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Takeda Pharmaceutical Company shares in existence, roughly 0 shares are currently held short) or 0.0021% of the tradable shares (for every 100,000 tradable Takeda Pharmaceutical Company shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Takeda Pharmaceutical Company.
Dividend payout ratio: 27.87% of net profits
Recently Takeda Pharmaceutical Company has paid out, on average, around 27.87% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.9% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical Company shareholders could enjoy a 5.9% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical Company's case, that would currently equate to about $180 per share.
While Takeda Pharmaceutical Company's payout ratio might seem fairly standard, it's worth remembering that Takeda Pharmaceutical Company may be investing much of the rest of its net profits in future growth.
Takeda Pharmaceutical Company's most recent dividend payout was on 14 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 29 March 2021 (the "ex-dividend date").
Over the last 12 months, Takeda Pharmaceutical Company's shares have ranged in value from as little as $14.02 up to $19.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical Company's is 1.1019. This would suggest that Takeda Pharmaceutical Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc. ; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.
ProShares Bitcoin Strategy ETF is the first fund tied to the value of a cryptocurrency to trade on the major U.S. markets. Here’s how to invest if you’re in Singapore.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.